Zoledronic acid
- Generic Name
- Zoledronic acid
- Brand Names
- Aclasta, Reclast, Zometa, Zoledronic Acid Accord, Zoledronic acid Actavis, Zoledronic acid medac, Zoledronic acid Teva, Zoledronic Acid Hospira, Zoledronic acid Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C5H10N2O7P2
- CAS Number
- 118072-93-8
- Unique Ingredient Identifier
- 70HZ18PH24
- Background
Zoledronic acid, or CGP 42'446, is a third generation, nitrogen containing bisphosphonate similar to ibandronic acid, minodronic acid, and risedronic acid. Zoledronic acid is used to treat and prevent multiple forms of osteoporosis, hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, and Paget’s disease of bone. Zoledronic acid was first described in the literature in 1994.
Zoledronic acid was granted FDA approval on 20 August 2001.
- Indication
Zoledronic acid is indicated to treat hypercalcemia of malignancy, multiple myeloma, bone metastases from solid tumors, osteoporosis in men and postmenopausal women, glucocorticoid induced osteoporosis, and Paget's disease of bone in men and women. Zoledronic acid is also indicated for the prevention of osteoporosis in post menopausal women and glucocorticoid induced osteoporosis.
- Associated Conditions
- Bone Metastases, Hypercalcemia of Malignancy, Multiple Myeloma (MM), Osteoporosis, Osteoporosis caused by Glucocorticoid Treatment, Paget's Disease of Bone, Paget’s Disease
- Associated Therapies
- Bone Mineral Density
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
- Conditions
- Interventions
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2018-08-14
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 39
- Registration Number
- NCT00482378
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Novartis
- Registration Number
- NCT00477217
- Locations
- 🇦🇺
Novartis Investigative Site, Gordon, Australia
Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma
- Conditions
- Interventions
- First Posted Date
- 2007-05-07
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 318
- Registration Number
- NCT00470223
- Locations
- 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷CHR de Besancon - Hopital Saint-Jacques, Besancon, France
🇫🇷CHU Hopital A. Morvan, Brest, France
Comparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone
- Conditions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- University of Leeds
- Target Recruit Count
- 1500
- Registration Number
- NCT00458796
- Locations
- 🇬🇧
Western Infirmary, Glasgow, Scotland, United Kingdom
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom
🇬🇧Withybush General Hospital, Haverfordwest, Wales, United Kingdom
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2011-04-20
- Lead Sponsor
- Novartis
- Target Recruit Count
- 412
- Registration Number
- NCT00439244
- Locations
- 🇩🇪
Novartis Investigative site, Wuerzburg, Germany
🇪🇸Novartis Investigative Site, Valencia, Spain
Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 60
- Registration Number
- NCT00436917
- Locations
- 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00434317
- Locations
- 🇭🇺
Novartis Investigative Site, Szekesfehervar, Hungary
Long Term Efficacy and Safety of Zoledronic Acid Treatment in Patients With Bone Metastases
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 73
- Registration Number
- NCT00434447
- Locations
- 🇦🇺
Novartis Investigative Site, Frankston, Victoria, Australia
Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2012-07-04
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 68
- Registration Number
- NCT00432458
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
- Conditions
- Interventions
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2011-03-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 110
- Registration Number
- NCT00431444
- Locations
- 🇺🇸
Women's Health Research, Phoenix, Arizona, United States
🇺🇸Alegent Health, Omaha, Nebraska, United States
🇺🇸UMDNJ-Robert Wood Johnson Medical Center, New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.